Information Content of Five Nomograms for Outcomes in Prostate Cancer
|
|
- Myron Mathews
- 6 years ago
- Views:
Transcription
1 Anatomic Pathology / NOMOGRAMS IN PROSTATE CANCER Information Content of Five Nomograms for Outcomes in Prostate Cancer Tarek A. Bismar, MD, 1 Peter Humphrey, MD, 2 and Robin T. Vollmer, MD 3 Key Words: Nomogram; Prostate cancer; Prostate-specific antigen; PSA; Gleason grade; Survival; Information; Entropy; Needle cores; Stage DOI: 1.139/XA419Q75F5D2TVJN Abstract In this study, we used 327 cases of localized prostate cancer to determine the information content provided by 5 popular nomograms for predicting outcomes in localized prostate cancer. All study patients underwent radical prostatectomy. For each case and each nomogram, we calculated the estimated probability of outcome, and, from this probability, we calculated the information content as 1 S, where S is the entropy. With this definition, information content is minimized at and maximized at 1. We found that the average information content ranged from.16 for the Partin tables to.44 for the recent Kattan nomogram for 1-year disease-free survival. Furthermore, the Kattan 1-year nomogram provided information content greater than.5 for 5% of study cases, so that among these 5 nomograms, we judged its performance the best. Nevertheless, because even this nomogram provided less than.5 information content for 5% of our cases, we believe that it can be improved and that additional measurements or markers observed on the biopsy tissues are likely to produce better nomograms. Many articles dealing with prostate cancer introduce the subject by quoting statistics on incidence and fatality. Herein, we do the same. The expected number of men to be diagnosed with prostate cancer in the United States in 27 is 218,89, and the expected number to die of this disease is 27,5. 1 To us, however, the most striking thing about these 2 numbers is not their magnitude, but their discrepancy. The difference between these 2 numbers underscores one of the many uncertainties regarding outcomes for prostate cancer. Many men get this disease, but most do not die of it. For most men with prostate cancer, their tumor is of localized stage, and most men treated by surgery or radiation therapy are cured. Yet, there remains uncertainty about whether such treatment is always necessary, and there is uncertainty about how to recognize men for whom neither surgery nor radiation treatment will be curative. To deal with such uncertainties and to provide useful information to men newly diagnosed with prostate cancer, some have derived algorithms or nomograms to predict the probability of important outcomes. 2 Most of these nomograms use pretreatment variables such as serum prostatespecific antigen (PSA) level and Gleason score, and many have validated their predictions with independent data. However, to our knowledge, no one has examined just how much uncertainty the nomograms resolve. Because uncertainty of outcome is directly related to the information theoretical concept of entropy, 3 we use here a measure of information derived from entropy. 4 Specifically, we evaluate the information provided by 5 popular nomograms for men with localized prostate cancer, and herein we report the results. Am J Clin Pathol 27;128: DOI: 1.139/XA419Q75F5D2TVJN 83
2 Bismar et al / NOMOGRAMS IN PROSTATE CANCER Materials and Methods Study Cases The study cases comprised 327, all of whom underwent radical prostatectomy. Of 327 men, 1 were diagnosed and treated at Washington University Medical Center, St Louis, MO; 132 at the Durham Veteran Affairs Medical Center, Durham, NC; and 95 at McGill University-Jewish General Hospital, Montreal, Canada. Other details about the patients and their tumors are given in Table 1. In this study, we used these 327 cases as prototypic cases to examine the amount of information to be expected from 5 nomograms that use preoperative variables to predict postoperative outcomes. Nomograms The nomograms we chose to examine comprised 5, which have proven popular to urologists and their patients and which provided sufficient details so that they could be executed on new data. For example, to apply the Partin nomogram we used the probability tables recently published. 5 These tables were based on the study of 5,79 men with localized prostate cancer, 5 and they rely on clinical stage, Gleason score, and the preoperative value of serum PSA to estimate the probability of organ-confined tumor status. Because the organ-confined state is significantly related to the long-term curative success of radical prostatectomy and because few patients nowadays undergo lymph node sampling, we restricted our analysis to the estimate of the probability of non organ confined tumor and did this for each study case. The second nomogram came from Shipley et al, 6 who studied 1,765 men treated with radiation therapy for localized prostate cancer. Shipley et al 6 derived a nomogram for predicting no evidence of tumor recurrence at 5 years based on follow-up values of PSA. Their algorithm came from a recursive partitioning model, and it used just PSA and Gleason score to Table 1 Characteristics of Study Population * Characteristic Result Age, y 63.6 (42-76) No. of cases by clinical stage T1c 192 T2 135 Serum PSA level, ng/ml 7.6 ( ) Total No. of biopsy cores 6.6 (1-12) Biopsy Gleason score 6.3 (4-1) No. with pt3 stage 15 * Data are given as mean (range) unless otherwise indicated. All values were measured during the preoperative period except for pt3 stage, which was determined from the prostatectomy specimen. Values are given in conventional units; to convert to Système International units (µg/l), multiply by 1.. form 4 prognostic groups with expected disease-free probabilities respectively of.81,.69,.47, and.29. As before, we applied this algorithm to our study cases. The third and fourth nomograms came from D Amico et al, 7 who provided tables of probabilities for tumor recurrence (manifested by a rising PSA level) within 2 years after surgery or external beam radiation treatment for men with localized prostate cancer. 7 Like the Partin algorithm, the D Amico algorithms use clinical stage, Gleason score, and the preoperative value of serum PSA, and their algorithms were derived from the study of 892 men who underwent surgery and 762 men who were treated with radiotherapy. From the tables, we then estimated the probability of tumor recurrence within 2 years for each study case. The fifth nomogram was that of Stephenson et al 8 for the probability of tumor recurrence at several times during followup after radical prostatectomy, and their results were derived from the study of 1,978 men who underwent surgery. 8-1 Because Kattan first introduced this approach 11 and was senior author for its most recent results, we will subsequently refer to this algorithm as the Kattan nomogram. This nomogram also relies on clinical stage, serum PSA level, and Gleason grade; and in addition, it uses the number of cores with tumor and the total number of cores taken. Each of these variables contributes to points, which then are totaled to achieve a prognostic point score. Finally, this model uses the Cox proportional hazards model to relate probability of a tumor-free state at various times to the total number of points. In our application, we concentrated on the probability of being cancer-free at 5 years. Because clinical stage T2 in our study cases was not subdivided into T2a, T2b, and T2c, we used a weighted mean to derive the appropriate probability or points to apply to cases with stage T2. Briefly, for each substage of T2, we formed a fraction equivalent to the relative frequency of that substage in the data of Stephenson et al. 8 We then multiplied this fraction by the probabilities listed for T2 stages in the Partin and D Amico tables or the points from the Kattan algorithm, and, finally, we summed these products to obtain a weighted mean for study cases with clinical stage T2. Calculation of Information Content We used a recently described method to calculate information content from the entropy, S, for a binary outcome. 4 Briefly, if p symbolizes the probability of a binary outcome like the presence of organ-confined prostate cancer, then the entropy, S, is defined as follows 4 : Equation 1 S = p * log 2 (p) (1 p) * log 2 (1 p) Here, log 2 is the logarithm to the base 2, and we use it here because for binary outcomes, this base of 2 guarantees that S will always be between and 1. Furthermore, for any 84 Am J Clin Pathol 27;128: DOI: 1.139/XA419Q75F5D2TVJN
3 Anatomic Pathology / ORIGINAL ARTICLE number x, the log 2 can be easily calculated from the natural logarithm to the base e by dividing the natural logarithm by.693. As before, we define the information content as 1 S. With this definition, the information content is highest (ie, a value of 1) when the outcome is certain, and it is lowest (ie, a value of ) when the outcome is no more certain than a coin toss. For example, when a nomogram estimates that the probability of a binary outcome is or 1, it is providing maximum information, and in both of these circumstances, 1 S equals 1. By contrast, when a nomogram estimates that the probability of a binary outcome is.5, it is providing no more information than a coin toss, and the value of 1 S equals. Thus, with this definition, the information content of 1 S tells us just how far toward certainty of outcome the nomogram will take us Figure 1 Information content provided by the Partin 5 nomogram for postsurgical outcome of organ-confined tumor on the study patients. Results In our study population, the Partin nomogram estimated that the probability of organ-confined tumor averaged.58 (range,.9-.92), and this implies that the information content averaged.16 (range, -.6). In other words, for the average study case, the Partin algorithm provided limited information about organ-confined status. Figure 1 shows a histogram of the information content for our entire study population, demonstrating in more detail the limited amount of information provided by the Partin algorithm for these typical prostatectomy cases. It also demonstrates that the most common information content was very nearly, ie, the information equivalent to a coin toss. The Shipley algorithm for PSA failure 5 years after radiotherapy yielded estimated probabilities averaging.77 in our study cases (range, ), and these results implied an average information content of.25 (range, -.3). A histogram of the information content provided by this nomogram is shown in Figure 2. The D Amico algorithm for PSA failure 2 years after surgery yielded estimated probabilities averaging.2 in our study cases (range,.4-.72), and these results implied an average information content of.32 (range, -.76). Thus, the D Amico algorithm provided more information for postsurgical outcome than did the Partin tables. A histogram of the information content provided by this nomogram is shown in Figure 3. The D Amico algorithm for PSA failure 2 years after external beam radiation therapy yielded estimated probabilities averaging.18 in our study cases (range,.3-.58), and these results implied an average information content of.37 (range, -.81), which was similar to the information provided by the D Amico postsurgical algorithm. A histogram of the information content provided by this nomogram is shown in Figure Figure 2 Information content provided by the Shipley 6 nomogram for postsurgical outcome of 5-year disease-free Figure 3 Information content provided by the D Amico 7 nomogram for postsurgical outcome of 2-year disease-free Am J Clin Pathol 27;128: DOI: 1.139/XA419Q75F5D2TVJN 85
4 Bismar et al / NOMOGRAMS IN PROSTATE CANCER Figure 4 Information content provided by the D Amico 7 nomogram for postradiation therapy outcome of 2-year disease-free Figure 5 Information content provided by the Kattan 11 nomogram for postsurgical outcome of 5-year disease-free In our study population, the Kattan nomogram estimated the probability for cancer-free recurrence at 5 years to average.83 (range, ), and this implies that the information content averaged.44 (range, -.8), a clear improvement over the preceding nomograms. Furthermore, for 5% of our study cases, this nomogram provided information content greater than.5, that is, greater than midway toward certainty. By contrast, for 29% of our study population, this nomogram provided information content less than.3. In other words, for these study cases, the information provided was just a fraction more than that provided by a coin toss. A histogram of the information content provided by this nomogram is shown in Figure 5. Discussion The results of this study, which are summarized in Table 2, suggest several conclusions. First, for an average patient with localized prostate cancer, none of these nomograms predicts a nearly certain outcome. Figures 1 through 5 demonstrate that for most of the study cases, the nomograms yielded information somewhere between that provided by a coin toss and midway to certainty. When compared with outcome information available without use of the prognostic variables in Table 2, these nomograms fare even worse. For example, the pooled 1-year disease-free survival obtained from several large studies of men after radical prostatectomy is 81%, 8,12-15 implying an information content of.3 for an average patient with localized tumor. Consequently, just 2 of the algorithms in Table 2 provide more information for an average patient than what is available without using the nomogram. From philosophical and religious points of view, this result should be no surprise, and perhaps even those favoring the collection of thousands of bits of molecular information will admit that predicting outcomes with near certainty is beyond human capability. The best we can hope for is to improve the average information content provided by the foregoing nomograms. Nevertheless, the results of this study are encouraging. For example, the information content provided by the Kattan nomogram was more than one third toward certainty for many of our study cases. The results also suggest that adding more variables increases information content. Because most of the information derived from pretreatment nomograms comes from things that Table 2 Summary of Variables Used and Results * Nomogram PSA Grade T Stage No. of Cores Mean 1 S Partin Not used.16 Shipley 3 2 Not used Not used.25 D Amico Not used.32 D Amico Not used.37 Kattan C 4 5 C.44 * All listed variables were determined preoperatively. Entries for the variables give the number of defined categories of the variable used in the nomogram, and an entry of C means that the variable was used as a continuous, or nearly continuous, one. The T stage refers to the clinical assignment of stage. The entry of mean 1 S provides the average information content of the nomogram applied to our study patients. The first D Amico nomogram is for postsurgical outcome and the second for postradiation therapy outcome. 86 Am J Clin Pathol 27;128: DOI: 1.139/XA419Q75F5D2TVJN
5 Anatomic Pathology / ORIGINAL ARTICLE pathologists observe, the results suggest that we should seek new prognostic information from the samples of tumor or serum already available to us. Because the Kattan nomogram uses the number of cores with tumor and the total numbers of cores taken, the results suggest that we need to include this information in our reports. And we can hope that ongoing studies of molecular markers will evolve into immunohistochemical markers that could improve these nomograms. The relative success of the Kattan nomogram suggests that continuous variables like serum PSA values and nearly continuous variables like number of cores should be used in their natural state rather than with a few cut points. Breaking a continuous prognostic variable like PSA into 3 to 5 categories, as done in the Partin, Shipley, and D Amico nomograms, discards information. Furthermore, the success of the Kattan nomogram favors the use of the PSA level as a nonlinear variable because that is how his nomogram used the PSA value. We suggest that good nomograms should pass 3 successive tests. First, they should use variables that are significantly associated with important outcomes. Second, they should be validated by application to new data. In other words, their results should provide accurate predictions for new data. Finally, they should provide real information content. It is not sufficient that a nomogram accurately predicts that a probability of an outcome is, say,.5, because this prediction provides no useful information. When the predicted probability is.5, the information content is. Good nomograms should routinely provide information content greater than.3 and frequently more than.5. From the 1 Departments of Pathology and Oncology, McGill University-Jewish General Hospital, Montreal, Canada; 2 Department of Pathology, Washington University School of Medicine, St Louis, MO; and 3 Department of Pathology, Veterans Affairs and Duke University Medical Centers, Durham, NC. Address reprint requests to Dr Vollmer: Laboratory Medicine 113, VA Medical Center, 58 Fulton St., Durham, NC References 1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 27. CA Cancer J Clin. 27;57: Ross PL, Scardino PT, Kattan MW. A catalog of prostate cancer nomograms. J Urol. 21;165: Giasu S. Information Theory With Applications. New York, NY: McGraw-Hill; Vollmer RT. Entropy and information content of laboratory test results. Am J Clin Pathol. 27;127: Partin AW, Kattan MW, Subong EN, et al. Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer: a multiinstitutional update. JAMA. 1997;277: Shipley WU, Thames HD, Sandler HM, et al. Radiation therapy for clinically localized prostate cancer: a multiinstitutional pooled analysis. JAMA. 1999;281: D Amico AV, Whittington R, Malkowicz SB, et al. Pretreatment nomogram for prostate-specific antigen recurrence after radical prostatectomy or external-beam radiation therapy for clinically localized prostate cancer. J Clin Oncol. 1999;17: Stephenson AJ, Scardino PT, Eastham JA, et al. Preoperative nomogram predicting the 1-year probability of prostate cancer recurrence after radical prostatectomy. J Natl Cancer Inst. 26;98: Graefen M, Karakiewicz PI, Cagiannos I, et al. International validation of a preoperative nomogram for prostate cancer recurrence after radical prostatectomy. J Clin Oncol. 22;2: Greene KL, Meng MV, Elkin EP, et al. Validation of the Kattan preoperative nomogram for prostate cancer recurrence using a community based cohort: results from cancer of the prostate strategic urological research endeavor (CaPSURE). J Urol. 24;171: Kattan MW, Eastham JA, Stapleton AMF, et al. A preoperative nomogram for disease recurrence following radical prostatectomy for prostate cancer. J Natl Cancer Inst. 1998;9: Gerber GS, Thisted RA, Scardino PT, et al. Results of radical prostatectomy in men with clinically localized prostate cancer: multi-institutional pooled analysis. JAMA. 1996;276: Krongrad A, Lai H, Lai S. Survival after radical prostatectomy. JAMA. 1997;278: Dillioglogil O, Leibman BD, Kattan MW, et al. Hazard rates for progression after radical prostatectomy for clinically localized prostate cancer. Urology. 1997;5: Pound CR, Partin AW, Epstein JI, et al. Prostate-specific antigen after anatomic radical retropubic prostatectomy. Urol Clin North Am. 1997;24: Am J Clin Pathol 27;128: DOI: 1.139/XA419Q75F5D2TVJN 87
concordance indices were calculated for the entire model and subsequently for each risk group.
; 2010 Urological Oncology ACCURACY OF KATTAN NOMOGRAM KORETS ET AL. BJUI Accuracy of the Kattan nomogram across prostate cancer risk-groups Ruslan Korets, Piruz Motamedinia, Olga Yeshchina, Manisha Desai
More informationCONTEMPORARY UPDATE OF PROSTATE CANCER STAGING NOMOGRAMS (PARTIN TABLES) FOR THE NEW MILLENNIUM
RAPID COMMUNICATION CME ARTICLE CONTEMPORARY UPDATE OF PROSTATE CANCER STAGING NOMOGRAMS (PARTIN TABLES) FOR THE NEW MILLENNIUM ALAN W. PARTIN, LESLIE A. MANGOLD, DANA M. LAMM, PATRICK C. WALSH, JONATHAN
More informationSince the beginning of the prostate-specific antigen (PSA) era in the. Characteristics of Insignificant Clinical T1c Prostate Tumors
2001 Characteristics of Insignificant Clinical T1c Prostate Tumors A Contemporary Analysis Patrick J. Bastian, M.D. 1 Leslie A. Mangold, B.A., M.S. 1 Jonathan I. Epstein, M.D. 2 Alan W. Partin, M.D., Ph.D.
More informationPreoperative Gleason score, percent of positive prostate biopsies and PSA in predicting biochemical recurrence after radical prostatectomy
JBUON 2013; 18(4): 954-960 ISSN: 1107-0625, online ISSN: 2241-6293 www.jbuon.com E-mail: editorial_office@jbuon.com ORIGINAL ARTICLE Gleason score, percent of positive prostate and PSA in predicting biochemical
More informationestimating risk of BCR and risk of aggressive recurrence after RP was assessed using the concordance index, c.
. JOURNAL COMPILATION 2008 BJU INTERNATIONAL Urological Oncology PREDICTION OF AGGRESSIVE RECURRENCE AFTER RP SCHROECK et al. BJUI BJU INTERNATIONAL Do nomograms predict aggressive recurrence after radical
More informationDivision of Urologic Surgery and Duke Prostate Center (DPC), Duke University School of Medicine, Durham, NC
LHRH AGONISTS: CONTEMPORARY ISSUES The Evolving Definition of Advanced Prostate Cancer Judd W. Moul, MD, FACS Division of Urologic Surgery and Duke Prostate Center (DPC), Duke University School of Medicine,
More informationSupplemental Information
Supplemental Information Prediction of Prostate Cancer Recurrence using Quantitative Phase Imaging Shamira Sridharan 1, Virgilia Macias 2, Krishnarao Tangella 3, André Kajdacsy-Balla 2 and Gabriel Popescu
More informationCorrelation of Gleason Scores Between Needle-Core Biopsy and Radical Prostatectomy Specimens in Patients with Prostate Cancer
ORIGINAL ARTICLE Correlation of Gleason Scores Between Needle-Core Biopsy and Radical Prostatectomy Specimens in Patients with Prostate Cancer Teng-Fu Hsieh, Chao-Hsian Chang, Wen-Chi Chen, Chien-Lung
More informationMultiinstitutional Validation of the UCSF Cancer of the Prostate Risk Assessment for Prediction of Recurrence After Radical Prostatectomy
2384 Multiinstitutional Validation of the UCSF Cancer of the Prostate Risk Assessment for Prediction of Recurrence After Radical Prostatectomy Matthew R. Cooperberg, MD, MPH 1 Stephen J. Freedland, MD
More informationNomograms for prostate cancer
Review Article NOMOGRAMS FOR PROSTATE CANCER STEPHENSON and KATTAN There are several papers in this section on various aspects of prostate cancer: predictive models, robotic radical prostatectomy in large
More informationNIH Public Access Author Manuscript World J Urol. Author manuscript; available in PMC 2012 February 1.
NIH Public Access Author Manuscript Published in final edited form as: World J Urol. 2011 February ; 29(1): 11 14. doi:10.1007/s00345-010-0625-4. Significance of preoperative PSA velocity in men with low
More informationPost Radical Prostatectomy Radiation in Intermediate and High Risk Group Prostate Cancer Patients - A Historical Series
Post Radical Prostatectomy Radiation in Intermediate and High Risk Group Prostate Cancer Patients - A Historical Series E. Z. Neulander 1, Z. Wajsman 2 1 Department of Urology, Soroka UMC, Ben Gurion University,
More informationDepartment of Urology, Inje University Busan Paik Hospital, Inje University College of Medicine, Busan, Korea
www.kjurology.org http://dx.doi.org/10.4111/kju.2014.55.5.321 Original Article - Urological Oncology http://crossmark.crossref.org/dialog/?doi=10.4111/kju.2014.55.5.321&domain=pdf&date_stamp=2014-05-16
More informationPredictors of time to biochemical recurrence in a radical prostatectomy cohort within the PSA-era
ORIGINAL RESEARCH Predictors of time to biochemical recurrence in a radical prostatectomy cohort within the PSA-era Ahva Shahabi, MPH, PhD; 1* Raj Satkunasivam, MD; 2* Inderbir S. Gill, MD; 2 Gary Lieskovsky,
More informationExternal validation of the Briganti nomogram to estimate the probability of specimen-confined disease in patients with high-risk prostate cancer
External validation of the Briganti nomogram to estimate the probability of specimen-confined disease in patients with high-risk prostate cancer Mathieu Roumiguié, Jean-Baptiste Beauval, Thomas Filleron*,
More informationPredictive Models. Michael W. Kattan, Ph.D. Department of Quantitative Health Sciences and Glickman Urologic and Kidney Institute
Predictive Models Michael W. Kattan, Ph.D. Department of Quantitative Health Sciences and Glickman Urologic and Kidney Institute Treatment for clinically localized prostate cancer Trade off: Substantial
More informationTHE MOST COMMON definitive therapy for the treatment
Postoperative Nomogram for Disease Recurrence After Radical Prostatectomy for Prostate Cancer Michael W. Kattan, Thomas M. Wheeler, and Peter T. Scardino Purpose: Although models exist that place patients
More informationKey words: prostatic neoplasms, risk groups, biochemical recurrence, clinical progression, prostate cancer specific mortality
JJCO Japanese Journal of Clinical Oncology Japanese Journal of Clinical Oncology, 2016, 46(8) 762 767 doi: 10.1093/jjco/hyw061 Advance Access Publication Date: 20 May 2016 Original Article Original Article
More informationTreatment Failure After Primary and Salvage Therapy for Prostate Cancer
307 Treatment Failure After Primary and Salvage Therapy for Prostate Cancer Likelihood, Patterns of Care, and Outcomes Piyush K. Agarwal, MD 1 Natalia Sadetsky, MD, MPH 2 Badrinath R. Konety, MD, MBA 2
More informationUse of the cell cycle progression (CCP) score for predicting systemic disease and response to radiation of biochemical recurrence
Cancer Biomarkers 17 (2016) 83 88 83 DOI 10.3233/CBM-160620 IOS Press Use of the cell cycle progression (CCP) score for predicting systemic disease and response to radiation of biochemical recurrence Michael
More informationPrognostic Value of Surgical Margin Status for Biochemical Recurrence Following Radical Prostatectomy
Original Article Japanese Journal of Clinical Oncology Advance Access published January 17, 2008 Jpn J Clin Oncol doi:10.1093/jjco/hym135 Prognostic Value of Surgical Margin Status for Biochemical Recurrence
More informationCorrespondence should be addressed to Taha Numan Yıkılmaz;
Advances in Medicine Volume 2016, Article ID 8639041, 5 pages http://dx.doi.org/10.1155/2016/8639041 Research Article External Validation of the Cancer of the Prostate Risk Assessment Postsurgical Score
More informationOutcomes of Radical Prostatectomy in Thai Men with Prostate Cancer
Original Article Outcomes of Radical Prostatectomy in Thai Men with Prostate Cancer Sunai Leewansangtong, Suchai Soontrapa, Chaiyong Nualyong, Sittiporn Srinualnad, Tawatchai Taweemonkongsap and Teerapon
More informationPCA MORTALITY VS TREATMENTS
PCA MORTALITY VS TREATMENTS Terrence P McGarty White Paper No 145 July, 2017 In a recent NEJM paper the authors argue that there is no material difference between a prostatectomy and just "observation"
More informationVictor H. W. Yeung, Yi Chiu, Sylvia S. Y. Yu, W. H. Au, and Steve W. H. Chan
The Scientific World Journal Volume 23, Article ID 5662, 4 pages http://dx.doi.org/.55/23/5662 Clinical Study Are Preoperative Kattan and Stephenson Nomograms Predicting Biochemical Recurrence after Radical
More informationUC San Francisco UC San Francisco Previously Published Works
UC San Francisco UC San Francisco Previously Published Works Title The quantitative Gleason score improves prostate cancer risk assessment Permalink https://escholarship.org/uc/item/9wq7g6k5 Journal Cancer,
More informationA Nomogram Predicting Long-term Biochemical Recurrence After Radical Prostatectomy
1254 A Nomogram Predicting Long-term Biochemical Recurrence After Radical Prostatectomy Nazareno Suardi, MD 1,2 Christopher R. Porter, MD 3 Alwyn M. Reuther, MD 4 Jochen Walz, MD 1,5 Koichi Kodama, MD
More informationDepartment of Urology, Nara Medical University, 840 Shijo-cho, Kashihara, Nara , Japan 2
Advances in Urology Volume 2012, Article ID 204215, 7 pages doi:10.1155/2012/204215 Research Article Calculated Tumor Volume Is an Independent Predictor of Biochemical Recurrence in Patients Who Underwent
More informationA NEURAL NETWORK PREDICTS PROGRESSION FOR MEN WITH GLEASON SCORE 3 4 VERSUS 4 3 TUMORS AFTER RADICAL PROSTATECTOMY
ADULT UROLOGY CME ARTICLE A NEURAL NETWORK PREDICTS PROGRESSION FOR MEN WITH GLEASON SCORE 3 4 VERSUS 4 3 TUMORS AFTER RADICAL PROSTATECTOMY MISOP HAN, PETER B. SNOW, JONATHAN I. EPSTEIN, THERESA Y. CHAN,
More informationeuropean urology 52 (2007)
european urology 52 (2007) 733 745 available at www.sciencedirect.com journal homepage: www.europeanurology.com Prostate Cancer Systematic Assessment of the Ability of the Number and Percentage of Positive
More informationPrognostic value of the Gleason score in prostate cancer
BJU International (22), 89, 538 542 Prognostic value of the Gleason score in prostate cancer L. EGEVAD, T. GRANFORS*, L. KARLBERG*, A. BERGH and P. STATTIN Department of Pathology and Cytology, Karolinska
More informationPredictive factors of late biochemical recurrence after radical prostatectomy
JJCO Japanese Journal of Clinical Oncology Japanese Journal of Clinical Oncology, 2017, 47(3) 233 238 doi: 10.1093/jjco/hyw181 Advance Access Publication Date: 9 December 2016 Original Article Original
More informationOutcomes Following Negative Prostate Biopsy for Patients with Persistent Disease after Radiotherapy for Prostate Cancer
Clinical Urology Post-radiotherapy Prostate Biopsy for Recurrent Disease International Braz J Urol Vol. 36 (1): 44-48, January - February, 2010 doi: 10.1590/S1677-55382010000100007 Outcomes Following Negative
More informationClinical Study Oncologic Outcomes of Surgery in T3 Prostate Cancer: Experience of a Single Tertiary Center
Advances in Urology Volume 22, Article ID 64263, 8 pages doi:.55/22/64263 Clinical Study Oncologic Outcomes of Surgery in T3 Prostate Cancer: Experience of a Single Tertiary Center D. Milonas, G. Smailyte,
More informationUnderstanding the risk of recurrence after primary treatment for prostate cancer. Aditya Bagrodia, MD
Understanding the risk of recurrence after primary treatment for prostate cancer Aditya Bagrodia, MD Aditya.bagrodia@utsouthwestern.edu 423-967-5848 Outline and objectives Prostate cancer demographics
More informationRadical prostatectomy as radical cure of prostate cancer in a high risk group: A single-institution experience
MOLECULAR AND CLINICAL ONCOLOGY 1: 337-342, 2013 Radical prostatectomy as radical cure of prostate cancer in a high risk group: A single-institution experience NOBUKI FURUBAYASHI 1, MOTONOBU NAKAMURA 1,
More informationZonal Origin of Localized Prostate Cancer Does not Affect the Rate of Biochemical Recurrence after Radical Prostatectomy
european urology 51 (2007) 949 955 available at www.sciencedirect.com journal homepage: www.europeanurology.com Prostate Cancer Zonal Origin of Localized Prostate Cancer Does not Affect the Rate of Biochemical
More informationIntroduction. Original Article
bs_bs_banner International Journal of Urology (2015) 22, 363 367 doi: 10.1111/iju.12704 Original Article Prostate-specific antigen level, stage or Gleason score: Which is best for predicting outcomes after
More informationMedical Policy Manual. Topic: Systems Pathology in Prostate Cancer Date of Origin: December 30, 2010
Medical Policy Manual Topic: Systems Pathology in Prostate Cancer Date of Origin: December 30, 2010 Section: Laboratory Last Reviewed Date: April 2014 Policy No: 61 Effective Date: July 1, 2014 IMPORTANT
More informationEvaluation of the 7th American Joint Committee on Cancer TNM Staging System for Prostate Cancer in Point of Classification of Bladder Neck Invasion
Jpn J Clin Oncol 2013;43(2)184 188 doi:10.1093/jjco/hys196 Advance Access Publication 5 December 2012 Evaluation of the 7th American Joint Committee on Cancer TNM Staging System for Prostate Cancer in
More informationChapter 6. Long-Term Outcomes of Radical Prostatectomy for Clinically Localized Prostate Adenocarcinoma. Abstract
Chapter 6 Long-Term Outcomes of Radical Prostatectomy for Clinically Localized Prostate Adenocarcinoma Vijaya Raj Bhatt 1, Carl M Post 2, Sumit Dahal 3, Fausto R Loberiza 4 and Jue Wang 4 * 1 Department
More informationLong-Term Risk of Clinical Progression After Biochemical Recurrence Following Radical Prostatectomy: The Impact of Time from Surgery to Recurrence
EUROPEAN UROLOGY 59 (2011) 893 899 available at www.sciencedirect.com journal homepage: www.europeanurology.com Platinum Priority Prostate Cancer Editorial by Bertrand D. Guillonneau and Karim Fizazi on
More informationAccuracy of post-radiotherapy biopsy before salvage radical prostatectomy
Accuracy of post-radiotherapy biopsy before salvage radical prostatectomy Joshua J. Meeks, Marc Walker*, Melanie Bernstein, Matthew Kent and James A. Eastham Urology Service, Department of Surgery and
More informationLong-term Oncological Outcome and Risk Stratification in Men with High-risk Prostate Cancer Treated with Radical Prostatectomy
Jpn J Clin Oncol 2012;42(6)541 547 doi:10.1093/jjco/hys043 Advance Access Publication 28 March 2012 Long-term Oncological Outcome and Risk Stratification in Men with High-risk Prostate Cancer Treated with
More informationBest Papers. F. Fusco
Best Papers UROLOGY F. Fusco Best papers - 2015 RP/RT Oncological outcomes RP/RT IN ct3 Utilization trends RP/RT Complications Evolving role of elnd /Salvage LND This cohort reflects the current clinical
More informationProstate Cancer: 2010 Guidelines Update
Prostate Cancer: 2010 Guidelines Update James L. Mohler, MD Chair, NCCN Prostate Cancer Panel Associate Director for Translational Research, Professor and Chair, Department of Urology, Roswell Park Cancer
More informationProviding Treatment Information for Prostate Cancer Patients
Providing Treatment Information for Prostate Cancer Patients For all patients with localized disease on biopsy For all patients with adverse pathology after prostatectomy See what better looks like Contact
More informationProstate Cancer: Is There Standard Treatment? Who has prostate cancer? In this article:
Focus on CME at l Université de Montréal Prostate Cancer: Is There Standard Treatment? Pierre I. Karakiewicz, MD, FRCSC; Paul Perrotte, MD, FRCSC; Fred Saad, MD, FRCSC In this article: 1. Risk factors
More informationSystems Pathology in Prostate Cancer. Description
Section: Medicine Effective Date: July 15, 2015 Subject: Systems Pathology in Prostate Cancer Page: 1 of 8 Last Review Status/Date: June 2015 Systems Pathology in Prostate Cancer Description Systems pathology,
More informationUC San Francisco UC San Francisco Previously Published Works
UC San Francisco UC San Francisco Previously Published Works Title Positive surgical margins in radical prostatectomy patients do not predict long-term oncological outcomes: Results from the Shared Equal
More informationCorrelation of Preoperative and Radical Prostatectomy Gleason Score: Examining the Predictors of Upgrade and Downgrade Results
ORIGINAL ARTICLE Correlation of Preoperative and Radical Prostatectomy Gleason Score: Examining the Predictors of Upgrade and Downgrade Results Gholamreza Pourmand, Shahram Gooran, Seyed Reza Hossieni,
More informationShort ( 1 mm) positive surgical margin and risk of biochemical recurrence after radical prostatectomy
Short ( 1 mm) positive surgical margin and risk of biochemical recurrence after radical prostatectomy Sergey Shikanov, Pablo Marchetti, Vikas Desai, Aria Razmaria, Tatjana Antic, Hikmat Al-Ahmadie*, Gregory
More informationUCSF UC San Francisco Previously Published Works
UCSF UC San Francisco Previously Published Works Title Patterns of practice in the United States: insights from CaPSURE on prostate cancer management. Permalink https://escholarship.org/uc/item/24j7405c
More informationWhen PSA fails. Urology Grand Rounds Alexandra Perks. Rising PSA after Radical Prostatectomy
When PSA fails Urology Grand Rounds Alexandra Perks Rising PSA after Radical Prostatectomy Issues Natural History Local vs Metastatic Treatment options 1 10 000 men / year in Canada 4000 RRP 15-year PSA
More informationSystems Pathology in Prostate Cancer
Systems Pathology in Prostate Cancer Policy Number: 2.04.64 Last Review: 8/2014 Origination: 8/2010 Next Review: 8/2015 Policy Blue Cross and Blue Shield of Kansas City (Blue KC) will not provide coverage
More informationDo all men with pathological Gleason score 8 10 prostate cancer have poor outcomes? Results from the SEARCH database
Do all men with pathological Gleason score 8 10 prostate cancer have poor outcomes? Results from the SEARCH database Sean Fischer*, Daniel Lin, Ross M. Simon*, Lauren E. Howard, William J. Aronson **,
More informationChapter 2. Understanding My Diagnosis
Chapter 2. Understanding My Diagnosis With contributions from Nancy L. Brown, Ph.D.,Palo Alto Medical Foundation Research Institute; and Patrick Swift, M.D., Alta Bates Comprehensive Cancer Program o Facts
More informationIntroduction. Key Words: high-grade prostatic intraepithelial neoplasia, HGPIN, radical prostatectomy, prostate biopsy, insignificant prostate cancer
Prostate cancer after initial high-grade prostatic intraepithelial neoplasia and benign prostate biopsy Premal Patel, MD, 1 Jasmir G. Nayak, MD, 1,2 Zlatica Biljetina, MD, 4 Bryan Donnelly, MD 3, Kiril
More informationDetection & Risk Stratification for Early Stage Prostate Cancer
Detection & Risk Stratification for Early Stage Prostate Cancer Andrew J. Stephenson, MD, FRCSC, FACS Chief, Urologic Oncology Glickman Urological and Kidney Institute Cleveland Clinic Risk Stratification:
More informationin 32%, T2c in 16% and T3 in 2% of patients.
BJUI Gleason 7 prostate cancer treated with lowdose-rate brachytherapy: lack of impact of primary Gleason pattern on biochemical failure Richard G. Stock, Joshua Berkowitz, Seth R. Blacksburg and Nelson
More informationJournal of American Science 2018;14(1)
Salvage Radiotherapy Following Radical Prostatectomy: The Proper Timing and Clinical Benefits Mohamed F. Sheta 1, MD, Esam A. Abo-Zena 1, MD and Mohamed H. Radwan 2, MD 1 Department of Clinical Oncology,
More informationWhen radical prostatectomy is not enough: The evolving role of postoperative
When radical prostatectomy is not enough: The evolving role of postoperative radiation therapy Dr Tom Pickles Clinical Associate Professor, UBC. Chair, Provincial Genito-Urinary Tumour Group BC Cancer
More informationPre-treatment risk stratification of prostate cancer patients: A critical review
REVIEW Pre-treatment risk stratification of prostate cancer patients: A critical review George Rodrigues, MD, FRCPC, MSc; * Padraig Warde, FRCPC, MB; Tom Pickles, MD, FRCPC; Juanita Crook, MD, FRCPC; ±
More informationPET imaging of cancer metabolism is commonly performed with F18
PCRI Insights, August 2012, Vol. 15: No. 3 Carbon-11-Acetate PET/CT Imaging in Prostate Cancer Fabio Almeida, M.D. Medical Director, Arizona Molecular Imaging Center - Phoenix PET imaging of cancer metabolism
More informationOncologic Outcome of Robot-Assisted Laparoscopic Prostatectomy in the High-Risk Setting
END-2010-0305-ver9-Engel_1P.3d 09/17/10 2:42pm Page 1 END-2010-0305-ver9-Engel_1P Type: research-article JOURNAL OF ENDOUROLOGY Volume 24, Number 00, XXXX 2010 ª Mary Ann Liebert, Inc. Pp. &&& &&& DOI:
More informationAnatomic distribution and pathologic characterization of small-volume prostate cancer (o0.5 ml) in whole-mount prostatectomy specimens
& 2005 USCAP, Inc All rights reserved 0893-3952/05 $30.00 www.modernpathology.org Anatomic distribution and pathologic characterization of small-volume prostate cancer (o0.5 ml) in whole-mount prostatectomy
More informationPost Radical Prostatectomy Adjuvant Radiation in Patients with Seminal Vesicle Invasion - A Historical Series
Post Radical Prostatectomy Adjuvant Radiation in Patients with Seminal Vesicle Invasion - A Historical Series E. Z. Neulander 1, K. Rubinov 2, W. Mermershtain 2, Z. Wajsman 3 1 Department of Urology, Soroka
More informationClinical Case Conference
Clinical Case Conference Intermediate-risk prostate cancer 08/06/2014 Long Pham Clinical Case 64 yo man was found to have elevated PSA of 8.65. TRUS-biopies were negative. Surveillance PSA was 7.2 in 3
More informationProstate Cancer. Axiom. Overdetection Is A Small Issue. Reducing Morbidity and Mortality
Overdetection Is A Small Issue (in the context of decreasing prostate cancer mortality rates and with appropriate, effective, and high-quality treatment) Prostate Cancer Arises silently Dwells in a curable
More informationGUIDELINES ON PROSTATE CANCER
10 G. Aus (chairman), C. Abbou, M. Bolla, A. Heidenreich, H-P. Schmid, H. van Poppel, J. Wolff, F. Zattoni Eur Urol 2001;40:97-101 Introduction Cancer of the prostate is now recognized as one of the principal
More informationGleason score = 8 prostate cancer: much more like Gleason score 9?
5 + 3 = 8 prostate cancer: much more like 9? Brandon A. Mahal, Vinayak Muralidhar*, Yu-Wei Chen, Toni K. Choueiri, Karen E. Hoffman, Jim C. Hu, Christopher J. Sweeney, James B. Yu**, Felix Y. Feng, Quoc-Dien
More informationEvaluation of prognostic factors after radical prostatectomy in pt3b prostate cancer patients in Japanese population
Japanese Journal of Clinical Oncology, 2015, 45(8) 780 784 doi: 10.1093/jjco/hyv077 Advance Access Publication Date: 15 May 2015 Original Article Original Article Evaluation of prognostic factors after
More informationRadical prostatectomy is the most widely used treatment. Partial Sampling of Radical Prostatectomy Specimens
ORIGINAL ARTICLE Detection of Positive Margins and Extraprostatic Extension Viacheslav Iremashvili, MD, PhD,* Soum D. Lokeshwar,* Mark S. Soloway, MD,* Lise tpelaez,md,w Saleem A. Umar, MD,w Murugesan
More informationABOUT MEN WILL BE
ORIGINAL CONTRIBUTION Comparison of ations by Urologists and Oncologists for Treatment of Clinically Localized Prostate Cancer Floyd J. Fowler, Jr, PhD Mary McNaughton Collins, MD, MPH Peter C. Albertsen,
More informationJ Clin Oncol 23: by American Society of Clinical Oncology INTRODUCTION
VOLUME 23 NUMBER 28 OCTOBER 1 2005 JOURNAL OF CLINICAL ONCOLOGY O R I G I N A L R E P O R T Predictors of Prostate Cancer Specific Mortality After Radical Prostatectomy or Radiation Therapy Ping Zhou,
More informationAlthough the test that measures total prostate-specific antigen (PSA) has been
ORIGINAL ARTICLE STEPHEN LIEBERMAN, MD Chief of Urology Kaiser Permanente Northwest Region Clackamas, OR Effective Clinical Practice. 1999;2:266 271 Can Percent Free Prostate-Specific Antigen Reduce the
More informationRisk Factors for Clinical Metastasis in Men Undergoing Radical Prostatectomy and Immediate Adjuvant Androgen Deprivation Therapy
RESEARCH ARTICLE Risk Factors for Clinical Metastasis in Men Undergoing Radical Prostatectomy and Immediate Adjuvant Androgen Deprivation Therapy Satoru Taguchi, Hiroshi Fukuhara*, Shigenori Kakutani,
More informationPSA Screening and Prostate Cancer. Rishi Modh, MD
PSA Screening and Prostate Cancer Rishi Modh, MD ABOUT ME From Tampa Bay Went to Berkeley Prep University of Miami for Undergraduate - 4 years University of Miami for Medical School - 4 Years University
More informationAccurate prediction of the biological potential of. Correlation between the Gleason Scores of Needle Biopsies and Radical Prostatectomy Specimens
Original Article 919 Correlation between the Gleason Scores of Needle Biopsies and Radical Prostatectomy Specimens Biing-Yir Shen, MD; Ke-Hung Tsui, MD; Phei-Lang Chang, MD; Cheng-Keng Chuang, MD, PHD;
More informationTREATMENT OPTIONS FOR LOCALIZED PROSTATE CANCER: QUALITY-ADJUSTED LIFE YEARS AND THE EFFECTS OF LEAD-TIME
ADULT UROLOGY TREATMENT OPTIONS FOR LOCALIZED PROSTATE CANCER: QUALITY-ADJUSTED LIFE YEARS AND THE EFFECTS OF LEAD-TIME VIBHA BHATNAGAR, SUSAN T. STEWART, WILLIAM W. BONNEY, AND ROBERT M. KAPLAN ABSTRACT
More informationComparative Risk-Adjusted Mortality Outcomes After Primary Surgery, Radiotherapy, or Androgen-Deprivation Therapy for Localized Prostate Cancer
Comparative Risk-Adjusted Mortality Outcomes After Primary Surgery, Radiotherapy, or Androgen-Deprivation Therapy for Localized Prostate Cancer Matthew R. Cooperberg, MD, MPH 1 ; Andrew J. Vickers, PhD
More informationthree after the most recent release in These modifications were based primarily on data from clinical, not pathological, staging [1].
. 2010 BJU INTERNATIONAL Urological Oncology PATHOLOGICAL T2 SUB-DIVISIONS AS A PROGNOSTIC FACTOR IN PROSTATE CANCER CASO ET AL. BJUI BJU INTERNATIONAL Pathological T2 sub-divisions as a prognostic factor
More informationApproximately 680,000 men are diagnosed with prostate
Prediction of Indolent Prostate Cancer: Validation and Updating of a Prognostic Nomogram E. W. Steyerberg,* M. J. Roobol, M. W. Kattan, T. H. van der Kwast, H. J. de Koning and F. H. Schröder From the
More informationThe Actual Value of the Surgical Margin Status as a Predictor of Disease Progression in Men with Early Prostate Cancer
european urology 50 (2006) 258 265 available at www.sciencedirect.com journal homepage: www.europeanurology.com Prostate Cancer The Actual Value of the Surgical Margin Status as a Predictor of Disease
More informationBiochemical recurrence-free survival and pathological outcomes after radical prostatectomy for high-risk prostate cancer
Beauval et al. BMC Urology (2016) 16:26 DOI 10.1186/s12894-016-0146-6 RESEARCH ARTICLE Open Access Biochemical recurrence-free survival and pathological outcomes after radical prostatectomy for high-risk
More informationRadiation Therapy After Radical Prostatectomy
Articles ISSN 1537-744X; DOI 10.1100/tsw.2004.93 Radiation Therapy After Radical Ali M. Ziada, M.D. and E. David Crawford, M.D. Division of Urology, University of Colorado, Denver, Colorado E-mails: aziada@mednet3.camed.eun.eg
More informationEarly outcomes of active surveillance for localized prostate cancer
Original Article ACTIVE SURVEILLANCE FOR LOCALIZED PROSTATE CANCER HARDIE et al. Early outcomes of active surveillance for localized prostate cancer CLAIRE HARDIE, CHRIS PARKER, ANDREW NORMAN*, ROS EELES,
More informationConceptual basis for active surveillance
Conceptual basis for active surveillance 1. Screening results in overdiagnosis 2. Clinically insignificant disease can be identified 3. All treatments have significant side effects and cost. 4. Delayed
More informationThe Role of the Pathologist Active Surveillance for Prostate Cancer
The Role of the Pathologist Active Surveillance for Prostate Cancer Thomas M. Wheeler, M.D. W. L. Moody, Jr., Professor and Chair Department of Pathology & Immunology Baylor College of Medicine Houston,
More informationDebate: Whole pelvic RT for high risk prostate cancer??
Debate: Whole pelvic RT for high risk prostate cancer?? WPRT well, at least it ll get the job done.or will it? Andrew K. Lee, MD, MPH Associate Professor Department of Radiation Oncology Using T-stage,
More informationPROSTATE-SPECIFIC ANTIGEN (PSA) is a sensitive
Prostate-Specific Antigen Doubling Times Are Similar in Patients With Recurrence After Radical Prostatectomy or Radiotherapy: A Novel Analysis By Bryan D. Leibman, Ozdal Dillioglugil, Peter T. Scardino,
More informationSalvage Radical Prostatectomy for Radiation-recurrent Prostate Cancer: A Multi-institutional Collaboration
EUROPEAN UROLOGY 60 (2011) 205 210 available at www.sciencedirect.com journal homepage: www.europeanurology.com Platinum Priority Prostate Cancer Editorial by Markus Graefen on pp. 211 213 of this issue
More informationElevated PSA. Dr.Nesaretnam Barr Kumarakulasinghe Associate Consultant Medical Oncology National University Cancer Institute, Singapore 9 th July 2017
Elevated PSA Dr.Nesaretnam Barr Kumarakulasinghe Associate Consultant Medical Oncology National University Cancer Institute, Singapore 9 th July 2017 Issues we will cover today.. The measurement of PSA,
More informationOne of the most important clinical applications of
PII S0009-9120(99)00099-5 Clinical Biochemistry, Vol. 33, No. 2, 115 123, 2000 Copyright 2000 The Canadian Society of Clinical Chemists Printed in the USA. All rights reserved 0009-9120/00/$ see front
More information1. INTRODUCTION. ARC Journal of Urology Volume 1, Issue 1, 2016, PP 1-7 Abstract:
ARC Journal of Urology Volume 1, Issue 1, 2016, PP 1-7 www.arcjournals.org Does the Number of Lymph Nodes Removed During Radical Prostatectomy Impact Risk of Biochemical Recurrence in Patients With Isolated
More informationPercentage of Gleason Pattern 4 and 5 Predicts Survival After Radical Prostatectomy
1967 Percentage of Gleason Pattern 4 and 5 Predicts Survival After Radical Prostatectomy Liang Cheng, MD 1,2 Darrell D. Davidson, MD, PhD 1 Haiqun Lin, MD, PhD 3 Michael O. Koch, MD 2 1 Department of Pathology
More informationClinical Study Evaluation of Serum Calcium as a Predictor of Biochemical Recurrence following Salvage Radiation Therapy for Prostate Cancer
ISRN Oncology Volume 2013, Article ID 239241, 7 pages http://dx.doi.org/10.1155/2013/239241 Clinical Study Evaluation of Serum Calcium as a Predictor of Biochemical Recurrence following Salvage Radiation
More informationInterval from Prostate Biopsy to Robot-Assisted Laparoscopic Radical Prostatectomy (RALP): Effects on Surgical Difficulties
www.kjurology.org http://dx.doi.org/10.4111/kju.2011.52.10.4 Urological Oncology Interval from Prostate Biopsy to RobotAssisted Laparoscopic Radical Prostatectomy (RALP): Effects on Surgical Difficulties
More informationInvasion of the muscular wall of the seminal vesicles by prostate cancer is generally
PROSTATE CANCER Seminal Vesicle Invasion by Prostate Cancer: Prognostic Significance and Therapeutic Implications Steven R. Potter, MD,* Jonathan I. Epstein, MD,* Alan W. Partin, MD, PhD* *The James Buchanan
More informationCase Discussions: Prostate Cancer
Case Discussions: Prostate Cancer Andrew J. Stephenson, MD FRCSC FACS Chief, Urologic Oncology Glickman Urological and Kidney Institute Cleveland Clinic Elevated PSA 1 54 yo, healthy male, family Hx of
More information